Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 1.27 [0.56, 2.89]
3 studies · 503 participants
Low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 0.63 [0.16, 2.52]
1 study · 125 participants
Very low